中国医药
中國醫藥
중국의약
China Medicine
2015年
12期
1786-1788
,共3页
中晚期胃癌%参芪扶正注射液%重组人血管内皮抑素%基质金属蛋白酶
中晚期胃癌%參芪扶正註射液%重組人血管內皮抑素%基質金屬蛋白酶
중만기위암%삼기부정주사액%중조인혈관내피억소%기질금속단백매
Advanced gastric cancer%Shenqi fuzheng injection%Human recombinant endostatin%Matrix metalloproteinases
目的 探讨参芪扶正注射液联合重组人血管内皮抑素治疗中晚期胃癌的疗效及对血清基质金属蛋白酶(MMP)2、MMP-7、MMP-11水平的影响.方法 选取2013年1月至2014年12月山东省滨州市中医医院收治的136例中晚期胃癌患者作为研究对象,回顾性分析其临床资料,按治疗方案不同分为对照组(64例)和观察组(72例).2组均给予常规FOLFOX化疗方案,对照组给予重组人血管内皮制素治疗(7.5 mg/m2静脉滴注,1次/d,给药14 d后休息1周,3周为1个疗程),观察组在对照组基础上联合应用参芪扶正注射液治疗(静脉滴注250 ml,1次/d,连续给药21 d为1个疗程),比较2组患者近期疗效、血清MMP-2、MMP-7、MMP-11水平及不良反应.结果 观察组、对照组近期治疗总有效率比较,差异无统计学意义[65.3％(47/72)比56.2％(36/64),P＞0.05].治疗后,2组血清MMP-2、MMP-7、MMP-11水平均明显低于治疗前[观察组:(4.1±1.0) μg/L比(5.0±1.4) μg/L、(9.4±1.0) μg/L比(16.9±1.1)μg/L、(33±3) μg/L比(43±4)μg/L;对照组:(4.7±1.1) μg/L比(5.0±1.2) μg/L、(13.1±1.0) μg/L比(16.8±1.2) μg/L、(38 ±3) μg/L比(42±4) μg/L],且观察组明显低于对照组,差异有统计学意义(P＜0.05).不良反应方面,观察组Ⅰ～Ⅱ度中性粒细胞减少和骨髓抑制发生率明显低于对照组,差异有统计学意义[20.8％(15/72)比37.5％ (24/64)、16.7％(12/72)比40.6％ (26/64),P＜0.05],而血红蛋白减少、血小板减少、胃肠道反应、手足综合征、肝功能损害等不良反应发生率组间比较差异无统计学意义(P＞0.05).结论 参芪扶正注射液联合重组人血管内皮抑素治疗中晚期胃癌疗效确切,不良反应减少,并且能够明显降低患者血清MMP-2、MMP-7、MMP-11水平.
目的 探討參芪扶正註射液聯閤重組人血管內皮抑素治療中晚期胃癌的療效及對血清基質金屬蛋白酶(MMP)2、MMP-7、MMP-11水平的影響.方法 選取2013年1月至2014年12月山東省濱州市中醫醫院收治的136例中晚期胃癌患者作為研究對象,迴顧性分析其臨床資料,按治療方案不同分為對照組(64例)和觀察組(72例).2組均給予常規FOLFOX化療方案,對照組給予重組人血管內皮製素治療(7.5 mg/m2靜脈滴註,1次/d,給藥14 d後休息1週,3週為1箇療程),觀察組在對照組基礎上聯閤應用參芪扶正註射液治療(靜脈滴註250 ml,1次/d,連續給藥21 d為1箇療程),比較2組患者近期療效、血清MMP-2、MMP-7、MMP-11水平及不良反應.結果 觀察組、對照組近期治療總有效率比較,差異無統計學意義[65.3％(47/72)比56.2％(36/64),P＞0.05].治療後,2組血清MMP-2、MMP-7、MMP-11水平均明顯低于治療前[觀察組:(4.1±1.0) μg/L比(5.0±1.4) μg/L、(9.4±1.0) μg/L比(16.9±1.1)μg/L、(33±3) μg/L比(43±4)μg/L;對照組:(4.7±1.1) μg/L比(5.0±1.2) μg/L、(13.1±1.0) μg/L比(16.8±1.2) μg/L、(38 ±3) μg/L比(42±4) μg/L],且觀察組明顯低于對照組,差異有統計學意義(P＜0.05).不良反應方麵,觀察組Ⅰ～Ⅱ度中性粒細胞減少和骨髓抑製髮生率明顯低于對照組,差異有統計學意義[20.8％(15/72)比37.5％ (24/64)、16.7％(12/72)比40.6％ (26/64),P＜0.05],而血紅蛋白減少、血小闆減少、胃腸道反應、手足綜閤徵、肝功能損害等不良反應髮生率組間比較差異無統計學意義(P＞0.05).結論 參芪扶正註射液聯閤重組人血管內皮抑素治療中晚期胃癌療效確切,不良反應減少,併且能夠明顯降低患者血清MMP-2、MMP-7、MMP-11水平.
목적 탐토삼기부정주사액연합중조인혈관내피억소치료중만기위암적료효급대혈청기질금속단백매(MMP)2、MMP-7、MMP-11수평적영향.방법 선취2013년1월지2014년12월산동성빈주시중의의원수치적136례중만기위암환자작위연구대상,회고성분석기림상자료,안치료방안불동분위대조조(64례)화관찰조(72례).2조균급여상규FOLFOX화료방안,대조조급여중조인혈관내피제소치료(7.5 mg/m2정맥적주,1차/d,급약14 d후휴식1주,3주위1개료정),관찰조재대조조기출상연합응용삼기부정주사액치료(정맥적주250 ml,1차/d,련속급약21 d위1개료정),비교2조환자근기료효、혈청MMP-2、MMP-7、MMP-11수평급불량반응.결과 관찰조、대조조근기치료총유효솔비교,차이무통계학의의[65.3％(47/72)비56.2％(36/64),P＞0.05].치료후,2조혈청MMP-2、MMP-7、MMP-11수평균명현저우치료전[관찰조:(4.1±1.0) μg/L비(5.0±1.4) μg/L、(9.4±1.0) μg/L비(16.9±1.1)μg/L、(33±3) μg/L비(43±4)μg/L;대조조:(4.7±1.1) μg/L비(5.0±1.2) μg/L、(13.1±1.0) μg/L비(16.8±1.2) μg/L、(38 ±3) μg/L비(42±4) μg/L],차관찰조명현저우대조조,차이유통계학의의(P＜0.05).불량반응방면,관찰조Ⅰ～Ⅱ도중성립세포감소화골수억제발생솔명현저우대조조,차이유통계학의의[20.8％(15/72)비37.5％ (24/64)、16.7％(12/72)비40.6％ (26/64),P＜0.05],이혈홍단백감소、혈소판감소、위장도반응、수족종합정、간공능손해등불량반응발생솔조간비교차이무통계학의의(P＞0.05).결론 삼기부정주사액연합중조인혈관내피억소치료중만기위암료효학절,불량반응감소,병차능구명현강저환자혈청MMP-2、MMP-7、MMP-11수평.
Objective To investigate the effect of Shenqi fuzheng injection combined with human recombinant endostatin in treating advanced gastric cancer and its influence on serum matrix netalloproteinase (MMP)-2, MMP-7, MMP-11.Methods Totally 136 patients with advanced gastric cancer from January 2013 to December 2014 were retrospectively analyzed.According to therapeutic schemes, the patients were divided into control group (64 cases) and observation group (72 cases).Both groups received FOLFOX regimen and human recombinant endostatin (7.5 mg/m2 , intravenous infusion, 1 time/d for 2 weeks, followed by 1 week break, 1 course consisted 3 weeks);observation group additionally received Shenqi fuzheng injection (250 ml,intravenous infusion, 1 time/d).The treatment was lasted for 2 courses.The short-term effective rate, the levels of serum MMP-2, MMP-7, MMP-11, the adverse reactions compared between groups.Results The total short-term effective rate in control group and observation group had no significant difference [65.3％ (47/72) vs 56.2％ (36/64)] (P ＞ 0.05).After treatment, the serum levels of MMP-2, MMP-7 and MMP-11 were significantly reduced compared with those before treatment in observation group [(4.1 ± 1.0) μg/L vs (5.0 ±1.4) μg/L, (9.4 ± 1.0) μg/L vs (16.9 ± 1.1) μg/L, (33 ± 3) μg/L vs (43 ± 4) μg/L] and control group [(4.7±1.1) μg/Lvs (5.0 ± 1.2) μg/L, (13.1 ± 1.0) μg/L vs (16.8 ± 1.2) pg/L, (38 ±3) μg/L vs (42 ±4) μg/L], moreover, they were much lower in observation group (P ＜0.05).As to the adverse reactions,the incidences of Ⅰ-Ⅱ degree neutropenia and myelosuppression in observation group were significantly lower than those in control group [20.8％ (15/72) vs 37.5％ (24/64), 16.7％ (12/72) vs 40.6％ (26/64)] (P ＜0.05), the incidences of hemoglobin reduction, thrombocytopenia, gastrointestinal reaction, hand-foot syndrome and liver function damage were not significantly different between groups.Conclusion Shenqi fuzheng injection combined with human recombinant endostatin is effective in treating advanced gastric cancer with less adverse reactions, and can decrease the levels of serum MMP-2, MMP-7, MMP-11.
